Research Protocol

Cagrilintide 10mg — Research Protocol

Dosage Calculator → How to Reconstitute →

Cagrilintide — 10mg protocol. Edit the doses below for the 10mg vial.

Quickstart Highlights

Cagrilintide is a long‑acting acylated analogue of the pancreatic hormone amylin, designed for once‑weekly subcutaneous administration[1]. It activates central amylin receptors to promote satiety, slow gastric emptying, and reduce food intake[2][3]. In phase 2 and phase 3 trials, cagrilintide produced dose‑dependent weight loss with a predominantly gastrointestinal side‑effect profile[4][5].

  • Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
  • Typical weekly range: 0.6–4.5 mg once weekly (gradual titration over 4–6 weeks).
  • Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 0.0333 mg (33.3 mcg) on a U‑100 insulin syringe.
  • Storage: Lyophilized: store frozen at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 30 days.

Dosing & Reconstitution Guide

 

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Route: Subcutaneous injection. Frequency: Once weekly on a consistent day.

Week/Phase Weekly Dose (mg) Units (per injection) Volume (mL)
Weeks 1–2 0.6 mg 18 units 0.18 mL
Weeks 3–4 1.2 mg 36 units 0.36 mL
Weeks 5–6 2.4 mg 72 units 0.72 mL
Weeks 7–16 (Maintenance) 4.5 mg 135 units 1.35 mL

Note: The maintenance dose of 4.5 mg requires 135 units (1.35 mL), which exceeds a standard U‑100 insulin syringe capacity. Use a 3 mL syringe with an appropriate subcutaneous needle (e.g., 25–27G, ½–⅝ inch) for doses above 1.0 mL. For titration doses (≤72 units), a U‑100 insulin syringe provides excellent accuracy.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming or vigorous agitation.
  3. Gently swirl or roll until fully dissolved (do not shake).
  4. Label with date and concentration; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use within 30 days of reconstitution; discard if cloudy or particulate matter appears.

Supplies Needed

Plan based on an 8–16 week weekly protocol with gradual titration.

  • Peptide Vials (Cagrilintide, 10 mg each):

     

    • 8 weeks ≈ 2 vials (17.4 mg total needed)
    • 12 weeks ≈ 4 vials (35.4 mg total needed)
    • 16 weeks ≈ 6 vials (53.4 mg total needed)
  • Syringes:

     

    • Weeks 1–6 (doses ≤72 units): U‑100 insulin syringes work well
    • Weeks 7+ (doses >100 units): 3 mL syringes with 25–27G subcutaneous needles
    • Per week: 1 syringe
    • 8 weeks: 8 syringes
    • 12 weeks: 12 syringes
    • 16 weeks: 16 syringes
  • Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.

     

    • 8 weeks (2 vials): 6 mL → 1 × 10 mL bottle
    • 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
    • 16 weeks (6 vials): 18 mL → 2 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each week.

     

    • Per week: 2 swabs
    • 8 weeks: 16 swabs
    • 12 weeks: 24 swabs
    • 16 weeks: 32 swabs → recommend 1 × 100‑count box

Protocol Overview

Protocol Overview

Concise summary of the once‑weekly regimen.

  • Goal: Support satiety, reduce food intake, and promote weight management over time[2][4].
  • Schedule: Weekly subcutaneous injections for 12–16 weeks (or longer as appropriate).
  • Dose Range: 0.6–4.5 mg weekly with gradual titration every 2 weeks.
  • Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for practical volume measurements.
  • Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw cycles.

Dosing Protocol

Suggested weekly titration approach based on clinical trial designs[1][6].

  • Start: 0.6 mg weekly for the first 2 weeks to assess tolerability.
  • Escalate: Double the dose every 2 weeks (0.6 → 1.2 → 2.4 → 4.5 mg) as tolerated.
  • Target: 4.5 mg weekly by Weeks 7–8; maintain at this dose.
  • Frequency: Once per week (subcutaneous) on the same day each week.
  • Timing: Any consistent time; rotate injection sites.

Storage Instructions

Proper storage preserves peptide integrity and potency.

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days and avoid freeze–thaw cycles.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and tolerability.

  • Use new sterile syringes for each injection; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) weekly to reduce local irritation.
  • Gradual dose escalation minimizes gastrointestinal side effects such as nausea[4][6].
  • Document weekly dose, injection site, and any adverse effects to maintain consistency.
  • For maintenance doses requiring >1.0 mL, ensure you have appropriately sized syringes (3 mL).

How It Works

Cagrilintide is an acylated, long‑acting analogue of amylin—a hormone co‑secreted with insulin from pancreatic beta cells[2][7]. Native amylin promotes satiation, slows gastric emptying, and inhibits postprandial glucagon secretion[8][9]. By acting on central amylin receptors (particularly in the area postrema and hindbrain), cagrilintide reduces appetite and energy intake[3][10]. Lipid modifications extend its half‑life to approximately 160–195 hours, enabling once‑weekly dosing[6][11].

Potential Benefits & Side Effects

Observations from phase 2 and phase 3 clinical trials.

  • Weight reduction: In the phase 2 trial, cagrilintide 4.5 mg weekly produced approximately 10.8% body weight loss over 26 weeks versus 3.0% with placebo[4].
  • Combination therapy: When combined with semaglutide 2.4 mg (CagriSema), phase 3 REDEFINE trials showed approximately 20% weight loss at 68 weeks, exceeding results with either agent alone[5][12].
  • Dose‑dependent efficacy: Higher doses (2.4–4.5 mg) demonstrate greater weight loss than lower doses (0.3–1.2 mg)[4].
  • Side effects: Primarily gastrointestinal—nausea, vomiting, diarrhea, and constipation—which are generally mild‑to‑moderate and transient[4][5]. Gradual titration helps minimize these effects.
  • Injection‑site reactions: Occasional mild redness or irritation at subcutaneous injection sites.

Lifestyle Factors

Complementary strategies for optimal outcomes.

  • Pair with a balanced, protein‑forward diet tailored to individual energy needs.
  • Combine resistance training and aerobic activity to support metabolic health and preserve lean mass.
  • Prioritize adequate sleep (7–9 hours) and stress management for adherence and recovery.
  • Monitor hydration and electrolytes, especially if experiencing gastrointestinal side effects.

References

References

For laboratory and research use only. Minimum 98% purity. Not intended for human or animal consumption, medical, diagnostic, therapeutic or veterinary use. These statements have not been evaluated by the MHRA or FDA. This protocol is provided for educational and research purposes only and is not medical advice. The purchaser accepts full responsibility for safe handling, storage and lawful use.